<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63111">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02284308</url>
  </required_header>
  <id_info>
    <org_study_id>ELDAPT</org_study_id>
    <nct_id>NCT02284308</nct_id>
  </id_info>
  <brief_title>Elderly With Locally Advanced Lung Cancer: Deciding Through Geriatric Assessment on the Optimal Treatment Strategy</brief_title>
  <acronym>ELDAPT</acronym>
  <official_title>ELDAPT: Elderly With Locally Advanced Lung Cancer: Deciding Through Geriatric Assessment on the oPtimal Treatment Strategy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht Radiation Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht Radiation Oncology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is no detailed information available on benefits and harms of intensified treatment
      with concurrent RCHT among a subpopulation of elderly patients. Reliable tools are needed to
      distinguish the subgroup of fit patients from frail patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lung cancer is a problem of the elderly: 30% of the lung cancer patients are aged ≥ 75
      years. Due to underrepresentation of elderly patients in clinical trials there is a lack of
      evidence to select the optimal treatment strategy for these patients. Concurrent
      radiochemotherapy (RCHT) has been recognised as the standard treatment of stage III NSCLC
      patients with a good performance status. Evidence for this treatment was gained in clinical
      trials that mostly excluded elderly patients. Furthermore, the survival gain obtained with
      combined RCHT, comes with a significant increase in toxicity. Therefore, information on
      benefits and harms of intensified treatment with concurrent RCHT among a subpopulation of
      medically fit elderly patients is still lacking. Moreover, reliable tools are needed to
      distinguish the subgroup of fit patients from frail patients, i.e. those expected to
      experience important toxicity.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>QAS (quality adjusted survival)</measure>
    <time_frame>yearly until death (average 10 years)</time_frame>
    <description>To compare concurrent and sequential RCHT with respect to quality-adjusted survival (QAS) in elderly patients (≥75 years) with stage III NSCLC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geriatric assessment</measure>
    <time_frame>Baseline</time_frame>
    <description>To perform geriatric assessment in stage III NSCLC patients to select patients fit enough to undergo intensified treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reliable predictive elements</measure>
    <time_frame>5 years</time_frame>
    <description>To identify reliable elements of the geriatric assessment that are predictive for treatment tolerance and QAS in elderly patients with stage III NSCLC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive value</measure>
    <time_frame>5 years</time_frame>
    <description>To determine the predictive value of blood biomarkers, cardiac ejection fraction and physical performance measures with respect to treatment tolerance and QAS in elderly patients with stage III NSCLC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development and validation of geriatric screening instrument</measure>
    <time_frame>5 years</time_frame>
    <description>To develop and validate a clinically applicable geriatric screening instrument that enables appropriate treatment stratification in the elderly NSCLC patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical comparison between treatments</measure>
    <time_frame>5 years</time_frame>
    <description>To compare concurrent and sequential RCHT in fit elderly patients with respect to overall and progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness</measure>
    <time_frame>End of study</time_frame>
    <description>To compare cost-effectiveness of sequential and concurrent RCHT for fit elderly patients with stage III NSCLC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical comparison between treatments with respect to preservation of functional capacity/independence</measure>
    <time_frame>5 years</time_frame>
    <description>To compare concurrent and sequential RCHT in fit elderly patients with respect to preservation of functional capacity/independence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical comparison between treatments with respect to overall and lung-cancer specific QOL</measure>
    <time_frame>5 years</time_frame>
    <description>Tom compare concurrent and sequential RCHT in fit elderly patients with respect to overall and lung-cancer specific Qol</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>Concurrent RCHT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Concurrent radiochemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequential RCHT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sequential radiochemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood withdrawal</intervention_name>
    <description>An extra withdrawal of blood, during a routine blood withdrawal</description>
    <arm_group_label>Concurrent RCHT</arm_group_label>
    <arm_group_label>Sequential RCHT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any subtype of NSCLC, primary UICC stage III

          -  Age ≥ 75 years

        Exclusion Criteria:

          -  Not any subtype of NSCLC, primary UICC stage III

          -  Younger than 75 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judith van Loon, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MAASTRO clinic (radiotherapist)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anne-Marie Dingemans, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>azM/MUMC (pulmonologist)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mariska Janssen-Heijnen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VieCuri Medical Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Judith van Loon, MD, PhD</last_name>
    <phone>+31 88 44 55 666</phone>
    <email>judith.vanloon@maastro.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chantal Overhof</last_name>
    <phone>+31 88 44 55 686</phone>
    <email>chantal.overhof@maastro.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Veerle Surmont</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ARTI</name>
      <address>
        <city>Arnhem</city>
        <zip>6815 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marcel Stam</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rijnstate Ziekenhuis</name>
      <address>
        <city>Arnhem</city>
        <zip>6815 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amphia Ziekenhuis</name>
      <address>
        <city>Breda</city>
        <zip>4818 CK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Centre Haaglanden</name>
      <address>
        <city>Den Haag</city>
        <zip>2512 VA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Klaar Maas</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>RISO</name>
      <address>
        <city>Deventer</city>
        <zip>7416 SE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ernest Vonk</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Catharina Hospital Eindhoven</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ben van den Borne</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Atrium medical centre</name>
      <address>
        <city>Heerlen</city>
        <zip>6419 PC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gerben Bootsma</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Centre</name>
      <address>
        <city>Leiden</city>
        <zip>2333 ZC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rajen Ramai</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MAASTRO clinic</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 ET</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Judith van Loon, MD, PhD</last_name>
      <phone>+31 88 44 55 666</phone>
      <email>judith.vanloon@maastro.nl</email>
    </contact>
    <contact_backup>
      <last_name>Chantal Overhof</last_name>
      <phone>+31 88 44 55 686</phone>
      <email>chantal.overhof@maastro.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne-Marie Dingemans, MD, PhD</last_name>
      <phone>+31 43 387 65 43</phone>
      <email>a.dingemans@maastro.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Centre Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Miep van der Drift</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Laurentius Hospital</name>
      <address>
        <city>Roermond</city>
        <zip>6043 VC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cordula Pitz</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>VieCuri Medical Centre</name>
      <address>
        <city>Venlo</city>
        <zip>5912 BL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marcel Westenend</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <lastchanged_date>November 30, 2015</lastchanged_date>
  <firstreceived_date>October 30, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
